Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INBX Inhibrx Biosciences

休市中 09-11 16:00:00 EDT

109.27

-2.15

-1.93%

盘后109.27

+0.000.00%

19:30 EDT

最高115.11	最低108.93	成交量21.10万
今开113.00	昨收111.42	日振幅5.55%
总市值16.03亿	流通市值9.44亿	总股本1,467万
成交额2,342万	换手率2.44%	流通股本863.89万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INBX","market":"US","secType":"STK","nameCN":"Inhibrx Biosciences","latestPrice":109.27,"timestamp":1789156800000,"preClose":111.42,"halted":0,"volume":211017,"hourTrading":{"tag":"盘后","latestPrice":109.27,"preClose":109.27,"latestTime":"19:30 EDT","volume":1034,"amount":113317.76,"timestamp":1789169404773,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.019296356129958767,"floatShares":8638900,"shares":14671186,"eps":-8.876818,"marketStatus":"休市中","change":-2.15,"latestTime":"09-11 16:00:00 EDT","open":113,"high":115.11,"low":108.93,"amount":23419249.06692,"amplitude":0.055466,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.876818,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":111.42,"preHourTrading":{"tag":"盘前","latestPrice":111.71,"preClose":111.42,"latestTime":"07:56 EDT","volume":10,"amount":1115.547,"timestamp":1789127806545,"change":0.29,"changeRate":0.002603,"amplitude":0.00718},"postHourTrading":{"tag":"盘后","latestPrice":109.27,"preClose":109.27,"latestTime":"19:30 EDT","volume":1034,"amount":113317.76,"timestamp":1789169404773,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.34977380902912486,"impliedVol":0.9525,"impliedVolPercentile":0.3466},"requestUrl":"/m/hq/s/INBX/wiki","defaultTab":"wiki","newsList":[{"id":"1140714808","title":"Inhibrx Biosciences公布实验性联合抗癌药中期研究数据后，股价重挫22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1140714808","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140714808?lang=zh_cn&edition=full","pubTime":"2026-09-08 22:18","pubTimestamp":1788877090,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences股价暴跌22%，缘于该公司披露了其试验性组合癌症药物的中期阶段研究数据。市场对此反应剧烈，股价应声大幅下挫。这家生物科技企业此番公布的数据，源于一项针对该联合疗法疗效和安全性的中段临床试验。投资者在审视这些最新出炉的结果后，显然对前景产生了疑虑，进而引发了抛售潮，拖累股价在交易时段内录得显著跌幅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144527689","title":"Inhibrx Biosciences：INBRX-106围手术期非小细胞肺癌Ⅰ/Ⅱ期临床试验进行中，初步结果预计2027年年中公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1144527689","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144527689?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:33","pubTimestamp":1788867232,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences正积极推进一项针对INBRX-106的Ⅰ/Ⅱ期临床研究，该试验聚焦于非小细胞肺癌（NSCLC）的围手术期治疗场景，初步数据有望于2027年年中揭晓。\n这家生物制药企业目前正全力投入INBRX-106的早期临床开发，探索其在非小细胞肺癌患者围手术期阶段的应用潜力。按照当前的时间表规划，研究团队期望能在2027年中期获取并公布首批关键性结果。\n颇具看点的是，这项研究不仅标志着INBRX-106临床适应症版图的进一步拓展，也折射出公司在肿瘤免疫治疗细分赛道的战略布局。围手术期策略的引入，意在更早期地介入肿瘤治疗流程，或将为患者带来全新的治疗契机。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187240423","title":"Inhibrx Biosciences：拟探索Inbrx-106与治疗性癌症疫苗联合应用的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1187240423","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187240423?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:32","pubTimestamp":1788867157,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences公司今日宣布，其战略布局将延伸至一个新的维度——探索其核心候选药物Inbrx-106与治疗性癌症疫苗的联合使用潜力。此举标志着该公司在肿瘤免疫治疗领域的创新步伐正进一步加快，意图通过多机制协同，开辟更广泛的抗肿瘤治疗路径。Inbrx-106作为该公司研发管线中的关键资产，其与癌症疫苗的潜在组合，不仅有望提升治疗响应率，更可能为当前应答不佳的患者群体带来新的曙光。公司方面对此寄予厚望，认为该联合策略或将在未来的临床开发中占据举足轻重的地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179108181","title":"Inhibrx Biosciences旗下INBRX-106在II期头颈鳞癌研究中：缓解率近乎翻倍，无进展生存期中位数达9.6个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1179108181","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179108181?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:31","pubTimestamp":1788867080,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences（INBX）公布了其候选药物INBRX-106在II期头颈鳞状细胞癌（HNSCC）临床研究中的中期数据。结果显示，该药物将缓解率提升近一倍，且无进展生存期（PFS）中位数达到了9.6个月，展现出令人鼓舞的抗肿瘤活性。这些数据预计将为后续的临床试验设计和潜在监管沟通提供关键支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135938113","title":"H.c. Wainwright首次覆盖Inhibrx Biosciences，给予买入评级及245美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1135938113","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135938113?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:09","pubTimestamp":1787566149,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences（INBX）近日获得H.c. Wainwright的正式关注。该机构首次覆盖这家生物科技公司，便果断给出“买入”评级，同时将目标股价设定在245美元。这一举动，无疑为市场注入了一剂强心针。245美元的目标价，相较于当前股价，意味着相当可观的潜在上行空间。此举也反映出华尔街对Inhibrx在研管线及技术平台所蕴含价值的初步认可。H.c. Wainwright此次的积极表态，标志着Inhibrx开始进入更多投资者的视野，其后续的研发进展和商业化潜力将成为市场关注的焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134591223","title":"Inhibrx Biosciences二次修订协议带来总计3.25亿美元资金，含1亿美元已到位与2.25亿美元可用额度","url":"https://stock-news.laohu8.com/highlight/detail?id=1134591223","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134591223?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:02","pubTimestamp":1784206950,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences公司通过其第二次修订协议，成功锁定了高达3.25亿美元的资金支持。该资金安排结构清晰，其中1亿美元已确认获得融资，另有2.25亿美元作为可用额度待后续启用。这一举措显著增强了公司的财务灵活性与研发推进能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188081691","title":"Inhibrx宣布与牛津金融修订贷款协议，总授信额度增至5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188081691","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188081691?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:01","pubTimestamp":1784206900,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences（INBX）已宣布与牛津金融（Oxford Finance）达成一项修订后的贷款协议。根据新协议，公司获得的总授信额度已扩大至5亿美元。此次修订旨在为公司提供更充足的财务灵活性，以支持其研发管线及运营需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174269329","title":"Inhibrx宣布美国FDA受理Ozekibart用于治疗常规软骨肉瘤患者的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1174269329","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174269329?lang=zh_cn&edition=full","pubTime":"2026-06-15 21:16","pubTimestamp":1781529384,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences（INBX）宣布，其用于治疗常规软骨肉瘤患者的在研药物Ozekibart的生物制品许可申请（BLA）已获得美国食品药品监督管理局（FDA）的受理。FDA的受理标志着该药物审评流程的正式启动，是向潜在获批迈出的关键一步。常规软骨肉瘤是一种罕见的骨癌，目前治疗选择有限，此次BLA的受理为患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169839556","title":"Inhibrx Biosciences公司：Inbrx-106联合帕博利珠单抗观察到三例完全影像学缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1169839556","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169839556?lang=zh_cn&edition=full","pubTime":"2026-05-11 20:06","pubTimestamp":1778501162,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences公司宣布，其候选药物Inbrx-106与帕博利珠单抗（Pembrolizumab）联合治疗的临床研究中，已观察到三例患者达到完全影像学缓解。\n这一积极数据展现了该联合疗法在特定患者群体中的显著抗肿瘤活性。完全影像学缓解通常意味着通过影像学检查（如CT或MRI）已无法检测到肿瘤病灶，是评估癌症治疗效果的一个重要指标。\n该结果进一步支持了Inbrx-106的开发潜力，为后续临床研究提供了有力依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181018288","title":"Inhibrx Biosciences公司：Inbrx-106联合帕博利珠单抗确认客观缓解率达44.0%，显著优于单药21.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181018288","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181018288?lang=zh_cn&edition=full","pubTime":"2026-05-11 20:05","pubTimestamp":1778501143,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences公司公布了其候选药物Inbrx-106与帕博利珠单抗联合疗法的积极数据。结果显示，该联合方案取得了44.0%的确认客观缓解率，而单独使用帕博利珠单抗的对照组，其确认客观缓解率仅为21.4%。这一数据对比凸显了联合疗法在疗效上的显著优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160098811","title":"Inhibrx Biosciences公司：Inbrx-106联合帕博利珠单抗或使系统性T细胞扩增提升高达15倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1160098811","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160098811?lang=zh_cn&edition=full","pubTime":"2026-05-11 20:02","pubTimestamp":1778500935,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences公司公布的最新研究数据显示，其候选药物Inbrx-106与帕博利珠单抗联合使用时，可能引发系统性T细胞扩增高达15倍的显著提升。这一发现预示着该联合疗法在激活人体免疫系统对抗肿瘤方面具有巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144007889","title":"Inhibrx公布INBRX-106一线治疗HNSCC的2期中期数据；初步结果显示其较PD-1单药疗法具有潜在共刺激优势","url":"https://stock-news.laohu8.com/highlight/detail?id=1144007889","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144007889?lang=zh_cn&edition=full","pubTime":"2026-05-11 20:01","pubTimestamp":1778500907,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences  公布了其候选药物INBRX-106在一线治疗头颈部鳞状细胞癌患者中的2期临床试验中期数据。初步分析表明，INBRX-106可能展现出超越现有PD-1单药疗法的共刺激活性优势，为这一治疗领域带来了新的希望。头颈部鳞状细胞癌的治疗长期面临挑战，尽管免疫检查点抑制剂如PD-1单抗已取得进展，但疗效提升空间依然显著。公司表示，这些数据支持继续推进INBRX-106的临床开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123068912","title":"Inhibrx 将举办网络直播 提供一线HNSCC中Inbrx-106六边形研究临床进展更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1123068912","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123068912?lang=zh_cn&edition=full","pubTime":"2026-05-09 04:01","pubTimestamp":1778270476,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences (INBX) 计划通过一场网络直播会议，对外公布其候选药物 Inbrx-106 在一线治疗头颈部鳞状细胞癌 (HNSCC) 的“六边形”研究中的最新临床数据。此次更新旨在向投资者和医学界提供该试验项目进展的关键信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111467807","title":"Inhibrx Biosciences盘前大涨6.2% 路透报道其实验性抗癌药物引默克及同业竞逐","url":"https://stock-news.laohu8.com/highlight/detail?id=1111467807","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111467807?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:08","pubTimestamp":1776856092,"startTime":"0","endTime":"0","summary":"生物科技公司Inhibrx Biosciences股价在盘前交易中强势攀升6.2%，此前路透社报道称，该公司旗下的一款实验性抗癌药物已吸引制药巨头默克及其竞争对手的收购兴趣。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156179722","title":"Inhibrx将举办网络直播会议 公布Ozekibart (INBRX-109)治疗晚期结直肠癌临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1156179722","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156179722?lang=zh_cn&edition=full","pubTime":"2026-04-21 05:05","pubTimestamp":1776719114,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences（纳斯达克代码：INBX）宣布将举办专题网络直播会议，重点介绍其核心候选药物Ozekibart（研发代号：INBRX-109）在晚期结直肠癌治疗领域的最新临床数据。此次会议将面向投资者和医学界专业人士，深入解析该药物在末线治疗中的疗效与安全性表现。\n公司管理层及临床研究负责人将出席本次会议，通过详实的数据展示与案例分析，全面呈现Ozekibart在难治性结直肠癌患者群体中的治疗潜力。与会者可通过在线平台实时参与互动研讨，获取第一手临床研究进展信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517645901","title":"Inhibrx Biosciences, Inc.盘中异动 大幅下跌5.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517645901","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517645901?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:25","pubTimestamp":1741274709,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时25分，Inhibrx Biosciences, Inc.股票出现异动，股价大幅跳水5.99%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.53%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306232509a2629e6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306232509a2629e6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677324","title":"Inhibrx Biosciences, Inc.盘中异动 早盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677324","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516677324?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:37","pubTimestamp":1741099056,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时37分，Inhibrx Biosciences, Inc.股票出现波动，股价急速跳水5.01%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422373696394681&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422373696394681&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516030626","title":"Inhibrx Biosciences, Inc.盘中异动 急速上涨5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516030626","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516030626?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:21","pubTimestamp":1740774085,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时21分，Inhibrx Biosciences, Inc.股票出现波动，股价快速上涨5.52%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301042126abe138c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301042126abe138c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513296523","title":"Inhibrx Biosciences, Inc.盘中异动 股价大涨12.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513296523","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513296523?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:33","pubTimestamp":1740148429,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时33分，Inhibrx Biosciences, Inc.股票出现波动，股价急速拉升12.34%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.34%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223350abd7b01d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223350abd7b01d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509259695","title":"Inhibrx Biosciences, Inc.盘中异动 临近收盘股价大涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509259695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509259695?lang=zh_cn&edition=full","pubTime":"2025-02-06 04:57","pubTimestamp":1738789060,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日04时57分，Inhibrx Biosciences, Inc.股票出现异动，股价急速上涨5.19%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.97%。其相关个股中，Immatics N V C/Wts 01/07/2025 、Invivyd, Inc.、Transcode Therapeutics, Inc.涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4731.93%、2453.39%、1790.40%，振幅较大的相关个股有Oragenics Inc.、Invivyd, Inc.、Transcode Therapeutics, Inc.，振幅分别为132.24%、108.79%、99.51%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206045740abc3cc61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206045740abc3cc61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inhibrx.com","stockEarnings":[{"period":"1week","weight":-0.0982},{"period":"1month","weight":0.1109},{"period":"3month","weight":0.1851},{"period":"6month","weight":0.5896},{"period":"1year","weight":2.8408},{"period":"ytd","weight":0.3832}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Inhibrx Biosciences, Inc.于2024年1月8日根据特拉华州法律成立，是Inhibrx, Inc.的直接全资子公司。该公司是一家临床阶段的生物制药公司，拥有一系列新型候选生物治疗药物，使用其专有的模块化蛋白质工程平台开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.100441},{"month":2,"riseRate":0,"avgChangeRate":-0.118883},{"month":3,"riseRate":0.25,"avgChangeRate":-0.108872},{"month":4,"riseRate":0.5,"avgChangeRate":-0.034815},{"month":5,"riseRate":0.25,"avgChangeRate":-0.039218},{"month":6,"riseRate":0.666667,"avgChangeRate":0.088726},{"month":7,"riseRate":0.666667,"avgChangeRate":0.111417},{"month":8,"riseRate":1,"avgChangeRate":0.030836},{"month":9,"riseRate":0.75,"avgChangeRate":0.016607},{"month":10,"riseRate":0.5,"avgChangeRate":0.197255},{"month":11,"riseRate":0.75,"avgChangeRate":0.223807},{"month":12,"riseRate":0.75,"avgChangeRate":0.232405}],"exchange":"NASDAQ","name":"Inhibrx Biosciences","nameEN":"Inhibrx Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inhibrx Biosciences(INBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inhibrx Biosciences,INBX,Inhibrx Biosciences股票,Inhibrx Biosciences股票老虎,Inhibrx Biosciences股票老虎国际,Inhibrx Biosciences行情,Inhibrx Biosciences股票行情,Inhibrx Biosciences股价,Inhibrx Biosciences股市,Inhibrx Biosciences股票价格,Inhibrx Biosciences股票交易,Inhibrx Biosciences股票购买,Inhibrx Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inhibrx Biosciences(INBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}